AbbVie's Immunogen Acquired Elahere Meets Primary Goal In Mid-Stage Study In Heavily Pretreated Ovarian Cancer Patients
Portfolio Pulse from Vandana Singh
AbbVie Inc (NYSE:ABBV) announced that its investigational drug Elahere met the primary endpoint in a Phase 2 trial for heavily pre-treated ovarian cancer patients. The study showed a 51.9% objective response rate and a median duration of response of 8.25 months. The safety profile was consistent with previous studies. Full data will be presented at a future medical meeting. Elahere, acquired through a $10 billion acquisition of Immunogen Inc, has also received FDA approval for certain ovarian cancer patients.
June 06, 2024 | 5:02 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
AbbVie's Elahere met the primary endpoint in a Phase 2 trial for heavily pre-treated ovarian cancer patients, showing a 51.9% objective response rate and a median duration of response of 8.25 months. The safety profile was consistent with previous studies, and no new safety concerns were identified. This positive result could boost investor confidence and potentially increase the stock price in the short term.
The positive trial results for Elahere, along with its recent FDA approval and acquisition of Immunogen, are likely to boost investor confidence in AbbVie's oncology pipeline. This could lead to a short-term increase in the stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100